Calreticulin (CALR) Mutation Screen available

Complementing our full myeloproliferative disease (MPD) diagnostic service, Viapath are pleased to let you know we are now offering the CALR mutation screen.

Myeloproliferative neoplasms (MPNs) are a group of diseases of the bone marrow in which excess cells are produced. They are related to, and may develop into, myelodysplastic syndrome and acute myeloid leukemia. To date, JAK2 has been the only reliable diagnostic tool available, leaving a third of patients with an incomplete diagnosis.

As part of our full MPD service offering, our Genetics division at Guy's and St Thomas' NHS Foundation Trust now offers molecular testing for Calreticulin mutation (CALR), a new test which aids diagnosis and classification of MPNs by revealing mutations in the majority of JAK2 and MPL mutation-negative patients.